Showing results (81-90 of 119) with videos related to
Sort By:
Pageof 12
Frontiers in Pharmacology|February 2, 2018
Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 TrialsToshiyuki Harada, Toraji Amano, Tomoo Ikari, et al.Cancer Chemotherapy and Pharmacology|October 9, 2014
Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902Kenya Kanazawa, Hiroshi Yokouchi, Xintao Wang, et al.ESMO Open|March 14, 2018
Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive <i>EGFR</i> mutationsSatoshi Oizumi, Shunichi Sugawara, Koichi Minato, et al.Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632Rintaro Noro, Satoshi Igawa, Akihiro Bessho, et al.Lung Cancer (Amsterdam, Netherlands)|September 5, 2020
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapyYusuke Okuma, Ryo Ko, Takehito Shukuya, et al.Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|December 28, 2023
Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and ThailandHiroshige Mikamo, Satoshi Takahashi, Yuka Yamagishi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2022
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, et al.Cancer Chemotherapy and Pharmacology|June 22, 2020
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703)Shin-Ichi Fukumoto, Satoshi Oizumi, Masao Harada, et al.Lung Cancer (Amsterdam, Netherlands)|April 19, 2021
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)Shotaro Ito, Hajime Asahina, Osamu Honjo, et al.International Journal of Clinical Oncology|July 21, 2018
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101)Taichi Takashina, Hajime Asahina, Satoshi Oizumi, et al.Pageof 12